ERBB2 and endometrial serous adenocarcinoma: In 2018, a randomized Phase II trial of carboplatin–paclitaxel versus carboplatin–paclitaxel–trastuzumab in uterine serous carcinomas with HER2/neu overexpression was conducted and showed that the addition of trastuzumab to carboplatin–paclitaxel was well-tolerated and increased progression-free survival [84].